Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00911495 · ClinicalTrials.gov registry record · Phase 1
Study of Intravenous GMI-1070 in Adults With Sickle Cell Disease
A Phase 1 study, sponsored by GlycoMimetics Incorporated.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT00911495: Completed Phase 1 study, sponsored by GlycoMimetics Incorporated.
NCT00911495 is a Phase 1 study that has completed, run by GlycoMimetics Incorporated. The registered enrollment target is 15 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00911495, a Phase 1 study, has completed, sponsored by GlycoMimetics Incorporated.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
This Phase 1/Phase 2 study will evaluate GMI-1070, a pan-selectin inhibitor, in adults with stable sickle cell disease. The study will assess safety, pharmacokinetics, and microvascular effects of intravenous GMI-1070 in the outpatient setting.
Interventions
- DRUG GMI-1070
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2009-05 |
| Est. Completion | 2010-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00911495
The ClinicalTrials.gov registry entry for NCT00911495 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlycoMimetics Incorporated, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GMI-1070 is the first listed.
NCT00911495 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00911495 about?
NCT00911495 is a clinical study titled "Study of Intravenous GMI-1070 in Adults With Sickle Cell Disease". This Phase 1/Phase 2 study will evaluate GMI-1070, a pan-selectin inhibitor, in adults with stable sickle cell disease. The study will assess safety, pharmacokinetics, and microvascular effects of intravenous GMI-1070 in the outpatient setting.
What is the current status of trial NCT00911495?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2009-05. Estimated completion is 2010-09.
What interventions are being tested in trial NCT00911495?
The interventions under investigation include: GMI-1070 (DRUG).
Who is sponsoring clinical trial NCT00911495?
This trial is sponsored by GlycoMimetics Incorporated, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.